Studying Fat-Released Particles and Blood Vessel Health in Obesity and Diabetes
Tests whether exercise training helps blood vessels in adults with obesity and diabetes.
Key facts
- Who runs it
- University of Illinois Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Registry title
- Role of Adiposomes in Endothelial Dysfunction
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 16 May 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Exercise training
- Record updated
- 17 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 50 with obesity and diabetes who are medically cleared for a moderate exercise program.
- Age
- 18 to 50 years
- Sex
- All sexes can join.
- Disease stage
- Obesity with a BMI of 35 kg/m2 or more, and diabetes (current use of diabetes medication or fasting glucose 126 mg/dL (7 mmol/L) or more).
Main reasons for not taking part
- Pregnant women
- Current smokers
- Currently abusing alcohol or drugs
- Chronic heart, liver or kidney disease, autoimmune disease or cancer
- History of allergic reactions to lidocaine
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- BMI ≥ 35 kg/m2
- Between ages 18-50 years
- Not pregnant
- Diabetic (Current use of diabetes medication or fasting glucose ≥126 mg/dL)
- Medical clearance to participate in a moderate-intensity exercise program
Who cannot take part
- Currently abusing alcohol or drugs
- Chronic heart, liver, or kidney diseases, autoimmune diseases, or cancer
- History of allergic reactions to lidocaine
- Pregnant women
- Current smokers
- Non-English speakers
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in United States
- University of Illinois at ChicagoChicago, United StatesContact: Abeer M Mohamed, MD, PhDTaking people
About the trial
What the trial wants to find out
The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event in the development of cardiovascular disease in obese diabetic (OB-T2D) patients, The investigators set their long-term goal to define molecular mechanisms of vascular dysfunction and corrective strategies that target these mechanisms such as physical activity and weight loss. The investigators recently discovered that human adipose tissues release extracellular vesicles (adiposomes) that are efficiently captured by endothelial cells. Adiposomes are known to carry bioactive cargos such as proteins and micro RNAs; however, their lipid content has not been studied nor has their ability to transfer their lipid cargo to endothelial cells. In the current application, the investigators propose to investigate the role of adiposomes in communicating the unhealthy milieu, mainly dysregulated lipids, to endothelial cells in OB-T2D subjects. On top of these lipid species that the investigators propose to be carried by adiposomes are glycosphingolipids (GSLs). These lipids originate from the glycosylation of ceramides, a chemical process that is upregulated in the presence of inflammation and high glucose levels. Preliminary findings showed that in endothelial cells, GSL-rich adiposomes disturb plasma membrane structure and subsequently induce endothelial dysfunction. Moreover, the investigators found that preconditioning endothelial cells with high shear stress (which is an exercise mimetic) protected endothelial cells from the detrimental effects induced by adiposomes. Therefore, the central hypothesis is that adipose tissues in OB-T2D patients release GSL-loaded adiposomes that induce vascular endothelial dysfunction. The researchers propose that exercise and weight loss interventions (bariatric surgery) will restore adipose tissue homeostasis, reduce GSL-loaded adiposomes, and subsequently alleviate vascular risk in OB-T2D patients. The investigators will test the hypotheses by pursuing the following aims: aim 1: Investigate the role of GSL-rich adiposomes in the pathogenesis of endothelial dysfunction in OB-T2D adults; aim 2: Test the effectiveness of exercise training in reducing adiposome-mediated effects on vascular function; and aim 3: Examine changes in adiposome/caveolae axis following metabolic surgery and their association with vascular function.
The 2 groups in the trial
- Exercise trainingTreatment being tested
Aerobic exercise training for 12 weeks, 3 times per week, 60 minutes per session.
- Control (standards of care)No study treatment, for comparison
This arm will receive brochures for healthy lifestyle recommendations. No intervention will be conducted.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Role of Adiposomes in Diabetes-Associated Endothelial Dysfunction and Restorative Effects of Exercise and Metabolic Surgery
- Plain-language title
- Studying Fat-Released Particles and Blood Vessel Health in Obesity and DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05199454, who can take part
- Record updated
- 17 August 2026